Second, we observed that the blocking of the PD-1/PD-L1 pathway by nivolumab increased the cytotoxicity of CIK cells targeted to NCI-H2228 rather than HCC-78 and A549 cells. Here, CD274 is linked to hepatocellular carcinoma.